Masimo Co. (NASDAQ:MASI) Given Consensus Recommendation of "Hold" by Brokerages

Masimo Co. (NASDAQ:MASI - Get Free Report) has earned an average recommendation of "Hold" from the seven brokerages that are currently covering the company, MarketBeat Ratings reports. Five research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $134.29.

MASI has been the topic of several analyst reports. Piper Sandler raised their price target on shares of Masimo from $70.00 to $117.00 and gave the company a "neutral" rating in a research note on Monday, February 26th. Jefferies Financial Group restated a "hold" rating and set a $121.00 target price (up from $107.00) on shares of Masimo in a report on Tuesday, January 30th. BTIG Research raised their target price on shares of Masimo from $145.00 to $166.00 and gave the stock a "buy" rating in a report on Monday, March 25th. Stifel Nicolaus raised their target price on shares of Masimo from $125.00 to $148.00 and gave the stock a "hold" rating in a report on Monday, March 25th. Finally, StockNews.com upgraded shares of Masimo from a "sell" rating to a "hold" rating in a report on Friday.

Hedge Funds Weigh In On Masimo

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its position in Masimo by 3.0% in the 2nd quarter. BlackRock Inc. now owns 6,120,123 shares of the medical equipment provider's stock worth $1,007,066,000 after buying an additional 178,267 shares in the last quarter. Vanguard Group Inc. lifted its position in Masimo by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 4,781,343 shares of the medical equipment provider's stock worth $560,421,000 after buying an additional 26,473 shares in the last quarter. Capital Research Global Investors lifted its position in Masimo by 6.4% in the 4th quarter. Capital Research Global Investors now owns 2,269,189 shares of the medical equipment provider's stock worth $265,972,000 after buying an additional 136,617 shares in the last quarter. State Street Corp lifted its position in Masimo by 1.6% in the 1st quarter. State Street Corp now owns 1,730,991 shares of the medical equipment provider's stock worth $251,928,000 after buying an additional 27,261 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Masimo by 6.2% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,607,310 shares of the medical equipment provider's stock worth $188,393,000 after buying an additional 93,861 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.

Masimo Stock Performance

MASI traded down $2.02 on Monday, hitting $144.83. 471,211 shares of the company's stock were exchanged, compared to its average volume of 614,125. The firm has a market cap of $7.66 billion, a PE ratio of 95.91 and a beta of 0.97. Masimo has a twelve month low of $75.22 and a twelve month high of $198.00. The stock has a fifty day moving average of $133.07 and a two-hundred day moving average of $110.25. The company has a current ratio of 2.18, a quick ratio of 1.22 and a debt-to-equity ratio of 0.64.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.43. Masimo had a net margin of 3.98% and a return on equity of 13.77%. The firm had revenue of $548.90 million for the quarter, compared to analyst estimates of $545.69 million. During the same quarter in the prior year, the business earned $1.32 earnings per share. Masimo's quarterly revenue was down 11.0% on a year-over-year basis. On average, research analysts anticipate that Masimo will post 3.51 earnings per share for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.